• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Cardano to Continue Rally

Cardano (ADA) is rising by 16.8% to $0.8550 this week, clearly outperforming Bitcoin (BTC), which is flat at $118,650. ADA broke through the key resistance level at $0.8000 on Thursday and surged to an intraday high of $0.8954. The token now appears poised to target the next major resistance at $1.0000, though a short-term pullback to retest the $0.8000 level is likely before any further advance.

Cardano continues to attract attention as a project of interest, with trading volumes on the rise — a strong sign of growing investor confidence. This momentum suggests that a sustained rally remains possible, especially if the broader crypto market maintains its current stability.

1138
B
8½ Weeks of Ripple Rally: Will There Be a Sequel?

As I told you two months ago, Ripple was going to greatly outperform Bitcoin dynamics, remaining a reliable investment option. The short-term benefits from Ripple are amazing, as the third most important crypto token first "took the Bastille" of $3.00 on July 14, and then hit a $3.5444 new historical high only three days later, when it gained about 16% within just twenty-four hours. The growth continues even as I write this text.

Trump's World Liberty Financial crypto fund is accelerating like lamps seen from an express train, representing billions and billions of dollars on paper. The project will provide enormous inflows into most usable tokens. Bitcoin scaled a record peaking price above $123,000, which is 14% above the post-election peaks of December 2024, but it has added less than 10% since mid-May, but Ripple is now up over 50% from the prices where I was actively buying it only 8,5 weeks ago. Someone can grab their profits here if they want. As for me, I will wait at least until a $5.50 target by Standard Chartered bank for the rest of 2025, which also mentioned a possible reach of as high as $8.00 in 2026. It is to double the capital even from current prices, it turns out, if one believes these estimates.

Trump and his close circle urged congressmen to make regulatory rules in favour of the crypto industry. There is a rising promise that the so-called stablecoin bills, which are the GENIUS Act and the Digital Asset Market CLARITY Act, will be passed before the weekend. The legislation initially failed in a House vote this Tuesday but is now expected to advance very soon. House Financial Services Committee chair French Hill told CNBC in an interview they have the necessary votes, so that there is strong bipartisan support for the bill. Again, there is the third bill to block the federal government from creating a central bank digital currency (CBDC) through the Federal Reserve unless it’s done with a specific authorization through Congress.

The crypto environment, and especially some selected coins, could simply thrive under such conditions, being replenished not only by exchange-traded funds, but also for the purpose of creating national reserves. If this is done in the US, then soon some other jurisdictions will follow, it is only a matter of time. If the world has recently cast aside all doubts about Bitcoin, then now confidence in some other altcoins will grow as well. It’s high time to switch to other solid and popular altcoins after such a strong bullish run in Bitcoin and Ethereum, and Ripple could be the best idea.

1027
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Maker Is Pushing Through the Resistance at $2000

Maker (MKR), also known as Sky, is rising by 1.3% to $1,901 this week, outperforming the broader crypto market where Bitcoin (BTC) is up just 0.4% to $118,120. MKR is once again approaching the key resistance level at $2,000 — its fifth attempt in the past three weeks. The repeated tests indicate growing pressure, but so far the token has struggled to decisively break through.

While the broader crypto environment is bullish, MKR continues to lag behind BTC's pace, reflecting its close correlation with general market sentiment rather than leading it. Speculation around Federal Reserve Chair Jerome Powell's possible resignation had briefly supported crypto assets, as markets anticipated a more dovish successor who might cut interest rates. However, U.S. President Donald Trump ultimately decided against removing Powell due to fears of a negative stock market reaction.

Without fresh, token-specific catalysts, MKR may find it difficult to sustain momentum beyond the $2,000 mark.

1301
B
J&J Boost High on Sales

Johnson & Johnson (JNJ) stock, which has been mostly consolidating for a little less than two years, all of a sudden got a rather promising future. The company substantially raised its annual sales guidance despite all those tariff-driven headwinds for the industry. The firm announced on July 16 that it now expects to post its revenue number within the higher range of $93.2 billion to $93.6 billion, up from its own previous estimate of $91 billion to $91.8 billion. So, even the conservative projection is higher than the previous optimistic one. This sounds amazing for the company, which is well known as a specialist in such a conservative segment as daily consumer healthcare goods, with also a diversified portfolio in pharmaceuticals and medical devices.

As to the quarterly routine, Johnson & Johnson also said its Q2 sales rose by 5.8% versus the same three-month period a year before to reach $23.74 billion vs analyst consensus of $22.84 billion, finding out an almost extra one billion of US Dollars somewhere, with Q2 EPS (earnings per share) of $2.77 to top forecast estimates of $2.68 as well. It now expects to add another billion or two in the remaining six months of the year. A much bigger lead in the score than I personally would have expected to see! Given that J&J shares have only gained about 2% to the $158+ area so far in pre-market trading today, I'm looking to grab them right now, expecting a retest of the $170 to $180 range over time, perhaps with such good inputs.

What's the way they do it, right? Its CEO Joseph Wolk cited demand fuelled by Darzalex blood cancer therapy, which showed better-than-projected sales of $3.54 billion. J&J also gave hope for some "game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular". Joseph Wolk also gave a comment on the tariff issue. Compared to his previous saying, based on the information available at the launch of Trump's tariff threats, that he anticipated a $400 million impact, now in the wake of a framework trade truce between the US and China, the hit is "probably" down to $200 million. Sounds like nothing more painful than a mosquito bite to such a giant seller. President Trump is going to unveil levies on pharmaceuticals likely by the end of July or early August, beginning with what he has once described as a "low tariff rate" to give businesses enough time to shift their manufacturing operations to the US territory. But he added that a "very high tariff" will then be into effect "in a year or so". That's why it's surely too early to forecast the company's prospect concerning 2026 results, but it's going to be fine for the rest of 2025.

They claim that they have calculated everything properly, even despite Stelara biosimilar competition. Stelara is a biologic medication designed for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease and ulcerative colitis. It basically works by targeting proteins in the immune system that cause inflammation. But what's important from the financial point of view that Stelara was made by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, so that Johnson & Johnson is the original manufacturer and marketer of Stelara, but there are now rather newly baked biosimilar versions available, made by Teva, Alvotech and Amgen. Those versions have also received US regulatory approval, clearly competing in sales with J&J's original medication.

While all this is happening, the company's inner forecasts have increased, and they also promised nice dividend numbers of $1.30 per share each quarter. Next time when the dividend will be payable is on September 9, 2025, to all stockholders of record on August 26. Those dividends are based on a 3.4% annual rate, and of course are far from the major argument when buying an asset or not, but I would not mind receiving them for a couple of quarters, if the asset itself also grows in price by some digits. This can't be compared with my return from AI investment, of course, but could be very interesting for the conservative part of my portfolio, instead of just cash or low-yield public bonds which I consider as a waste of money. Back to JNJ, monthly charts show that a multi-year support around $140 has been tested quickly but properly in early April during the overall tariff correction of Wall Street, the risk of losing something does not look significant, but a repeat of the 2020-2021 mini-rally for J&J looks like the baseline scenario.

1226
31

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors